Reporting owner · CIK 0001940272
Adar1 Capital Management, LLC
SEC Form 4 history across 2 companies, 19 transactions and 7 filings.
10%InMed Pharmaceuticals Inc.
Open-market transaction mix100% buys19 buys · 0 sales
Available history · Aug 20, 2026 – Oct 15, 2026
Latest insider transactions
Form 4 filings from available history.Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
buy at InMed Pharmaceuticals Inc. on Oct 15, 2026 valued at $1,301.
Review SEC filingLatest sale
No open-market insider sale is available.
Monthly open-market activity
Last 3 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Aug 2026 | 4 | 0 | $2,536,741.36 | $0.00 | $2,536,741.36 |
| Sep 2026 | 6 | 0 | $2,381,391.92 | $0.00 | $2,381,391.92 |
| Oct 2026 | 9 | 0 | $84,283.38 | $0.00 | $84,283.38 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$263.3K
Median P/S size$24.2K
Direct0
Indirect19
Oct 15, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
12 observations · Sep 14, 2026 – Oct 15, 2026. Window ends at the latest available report, not today.
Selected observation · Oct 15, 2026955,493 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 14, 2026 | 829,505 | Sep 16, 2026 | View transaction |
| Sep 15, 2026 | 883,761 | Sep 16, 2026 | View transaction |
| Sep 16, 2026 | 892,101 | Sep 16, 2026 | View transaction |
| Oct 1, 2026 | 908,532 | Oct 5, 2026 | View transaction |
| Oct 2, 2026 | 916,839 | Oct 5, 2026 | View transaction |
| Oct 5, 2026 | 935,021 | Oct 5, 2026 | View transaction |
| Oct 6, 2026 | 940,622 | Oct 8, 2026 | View transaction |
| Oct 7, 2026 | 943,668 | Oct 8, 2026 | View transaction |
| Oct 8, 2026 | 945,924 | Oct 8, 2026 | View transaction |
| Oct 13, 2026 | 946,488 | Oct 15, 2026 | View transaction |
| Oct 14, 2026 | 954,509 | Oct 15, 2026 | View transaction |
| Oct 15, 2026 | 955,493 | Oct 15, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Adar1 Capital Management, LLC Insider Activity FAQ
SEC Form 4 context
Who is Adar1 Capital Management, LLC?
Adar1 Capital Management, LLC is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001940272.
Which companies has Adar1 Capital Management, LLC reported transactions for?
InMed Pharmaceuticals Inc., TENAX THERAPEUTICS, INC.
When was Adar1 Capital Management, LLC's latest insider buy?
buy at InMed Pharmaceuticals Inc. on Oct 15, 2026 valued at $1,301.
When was Adar1 Capital Management, LLC's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.